Zilebesiran Shows Potential in Lowering Blood Pressure in High-Risk Hypertensive Patients
Clinical trial data suggests that zilebesiran, an investigational RNA therapy, may help lower blood pressure in high-risk hypertensive patients, paving the way for new treatment options.
Recent clinical trial results reveal that a single subcutaneous dose of zilebesiran, an investigational RNA interference therapy, has the potential to reduce blood pressure in patients with uncontrolled hypertension and a high risk of cardiovascular disease. The phase II KARDIA-3 trial, conducted across five countries, focused on adult patients with established cardiovascular conditions or high risk factors, who were already on multiple antihypertensive medications but still had elevated blood pressure readings. The study analyzed the effects of zilebesiran at doses of 300 mg and 600 mg compared to placebo, observing changes over a three- to six-month period.
Results indicated a trend toward lower systolic blood pressure (SBP), with patients receiving 300 mg showing a mean reduction of 5 mmHg at three months, although this did not achieve statistical significance. Similar patterns were observed at six months, especially in 24-hour ambulatory blood pressure monitoring, where zilebesiran at both doses lowered SBP by approximately 5 to 7 mmHg compared to placebo. A notable post-hoc analysis showed greater blood pressure reduction in patients already on diuretics and with higher baseline SBP.
Safety assessments demonstrated that most adverse events were mild or moderate and transient, with serious adverse events being rare and comparable across groups. The findings suggest that while the primary endpoints did not reach statistical significance, the data support further investigation of zilebesiran in larger, more definitive phase III trials. As Dr. Neha Pagidipati emphasized, this study provides valuable insights that will inform future research aimed at improving hypertension management and cardiovascular outcomes.
High blood pressure remains a significant contributor to global mortality, and new treatments like zilebesiran could offer more effective options, especially for patients who struggle with achieving blood pressure control using current therapies.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of Birth Location on Survival and Hospital Stay for Very Preterm Infants
A recent study reveals that the birthplace of very preterm infants significantly influences their survival and duration of hospital stay, highlighting opportunities for healthcare quality improvements.
AI-Driven Echocardiography Enhances Early Detection of Cardiac Amyloidosis
A new AI-powered echocardiography tool improves early detection of cardiac amyloidosis, enabling timely treatment and better patient outcomes. Developed by Mayo Clinic and Ultromics, this innovative system offers high accuracy in identifying amyloid buildup in the heart.
Understanding How Leukemia Virus Remains Hidden in the Body—Implications for Future Treatments
New research uncovers how HTLV-1, the virus linked to leukemia, remains hidden in the body through a genetic silencer. This discovery could lead to innovative therapies for retroviral infections like HIV and HTLV-1.
Benefits of Early Aspirin Discontinuation in Low-Risk Heart Attack Patients
Research shows that early discontinuation of aspirin after MI in low-risk patients can reduce bleeding risk without increasing adverse events, thanks to advancements in revascularization techniques.